P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer's disease: preliminary observations.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Neurobiology of Aging

• Publication date

  2015-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.neurobiolaging.2015.05.020PMID 26159621
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• R: A language and environment for statistical computing.

  2014cited by this paper
• Amyloid-beta accumulation, neurogenesis, behavior, and the age of rats.

  2014cited by this paper
• P-Glycoprotein Function at the Blood–Brain Barrier: Effects of Age and Gender

  2012cited by this paper
• An investigation into the role of P-glycoprotein in Alzheimer's disease lesion pathogenesis.

  2011cited by this paper
• Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years

  2011cited by this paper
• O1‐07‐04: Blood‐brain barrier p‐glycoprotein function in Alzheimer's disease

  2011cited by this paper
• Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent

  2011cited by this paper
• Beta-Amyloid Downregulates MDR1-P-Glycoprotein (Abcb1) Expression at the Blood-Brain Barrier in Mice

  2011cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• Amyloid Deposition and Influx Transporter Expression at the Blood-Brain Barrier Increase in Normal Aging

  2010influential reference
• Amyloid Efflux Transporter Expression at the Blood-Brain Barrier Declines in Normal Aging

  2010influential reference
• Evaluation of biodistribution and safety of adenovirus vector containing MDR1 in mice

  2010cited by this paper
• Alzheimer's disease.

  2010cited by this paper
• Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease

  2010cited by this paper
• Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease.

  2008cited by this paper
• Seizure-Induced Up-Regulation of P-Glycoprotein at the Blood-Brain Barrier through Glutamate and Cyclooxygenase-2 Signaling

  2008cited by this paper
• RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease

  2006cited by this paper
• Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system.

  2006cited by this paper
• P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model.

  2005cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease.

  2004cited by this paper
• Clearing amyloid through the blood–brain barrier

  2004cited by this paper
• Importance of P-glycoprotein at blood-tissue barriers.

  2004cited by this paper
• RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain

  2003cited by this paper
• Functional expression and localization of P‐glycoprotein at the blood brain barrier

  2002cited by this paper
• Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions.

  2002cited by this paper
• Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans.

  2002cited by this paper
• Multidrug-resistance protein 1 in focal cortical dysplasia.

  2001cited by this paper
• beta-Amyloid efflux mediated by p-glycoprotein.

  2001cited by this paper
• β‐Amyloid efflux mediated by p‐glycoprotein

  2001cited by this paper
• Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.

  2000cited by this paper
• Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease.

  1999cited by this paper
• Quantitative non-radioactive in situ hybridization study of GAP-43 and SCG10 mRNAs in the cerebral cortex of adult and infant macaque monkeys.

  1999cited by this paper
• Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

  1997cited by this paper
• Validation of Nonradioactive In Situ Hybridization as a Quantitative Approach of Messenger Ribonucleic Acid Variations: A Comparison With Northern Blot

  1997cited by this paper
• Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease.

  1997cited by this paper
• Cerebrovascular Permeability to Peptides: Manipulations of Transport Systems at the Blood-Brain Barrier

  1995cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1991cited by this paper
• Transport of Leucine‐Enkephalin Across the Blood‐Brain Barrier in the Perfused Guinea Pig Brain

  1987cited by this paper
• Blood-brain barrier permeability to leucine-enkephalin, D-alanine2-D-leucine5-enkephalin and their N-terminal amino acid (tyrosine).

  1985cited by this paper
• Evidence for a lactate transport system in the sarcolemmal membrane of the perfused rabbit heart: kinetics of unidirectional influx, carrier specificity and effects of glucagon.

  1985cited by this paper
• A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.

  1976cited by this paper

• Mechanistic modeling of amyloid dynamics relating to Alzheimer's disease progression.

  2026cites this paper
• Modeling neurovascular dysfunction in Alzheimer’s disease using an isogenic brain-chip model

  2026cites this paper
• Butyrate regulates the blood-brain barrier transport and intra-endothelial accumulation of Alzheimer’s disease Amyloid-beta peptides

  2025cites this paper
• P-glycoprotein and Alzheimer’s Disease: Threats and Opportunities

  2025cites this paper
• Vascular models of Alzheimer's disease: An overview of recent in vitro models of the blood-brain barrier.

  2025cites this paper
• The brain washing system in sepsis-associated encephalopathy

  2025cites this paper
• Systematic review of amyloid-beta clearance proteins from the brain to the periphery: implications for Alzheimer’s disease diagnosis and therapeutic targets

  2025cites this paper
• Cellular and molecular mechanisms of the blood–brain barrier dysfunction in neurodegenerative diseases

  2024cites this paper
• The Blood-Brain Barrier: Composition, Properties, and Roles in Brain Health.

  2024cites this paper
• Approaches for Increasing Cerebral Efflux of Amyloid-β in Experimental Systems

  2024cites this paper
• Enhancing of cerebral Abeta clearance by modulation of ABC transporter expression: a review of experimental approaches

  2024cites this paper
• Interactions between Beta-Amyloid and Pericytes in Alzheimer's Disease.

  2024cites this paper
• Machine learning-based virtual screening and molecular modelling studies for identification of butyrylcholinesterase inhibitors as anti-Alzheimer’s agent

  2024cites this paper
• The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases

  2024cites this paper
• Challenges and prospects in geriatric epilepsy treatment: the role of the blood–brain barrier in pharmacotherapy and drug delivery

  2024cites this paper
• Pathology of Amyloid-β (Aβ) Peptide Peripheral Clearance in Alzheimer’s Disease

  2024cites this paper
• Breaking barriers: the role of NETosis in blood-brain barrier leakage and age-related cognitive decline

  2024cites this paper
• Unveiling the hidden connection: the blood-brain barrier’s role in epilepsy

  2024cites this paper
• The aging brain and late onset drug-refractory epilepsies.

  2024cites this paper
• The potential role of gut microbiota-derived metabolites as regulators of metabolic syndrome-associated mitochondrial and endolysosomal dysfunction in Alzheimer’s disease

  2024cites this paper
• Proteomic Profiling Reveals Age-Related Changes in Transporter Proteins in the Human Blood-Brain Barrier

  2024cites this paper
• In Silico Interactions of Natural and Synthetic Compounds with Key Proteins Involved in Alzheimer’s Disease: Prospects for Designing New Therapeutics Compound

  2023cites this paper
• Rebuilding insight into the pathophysiology of Alzheimer's disease through new blood-brain barrier models

  2023cites this paper
• Blood-brain barrier transporters: An overview of function, dysfunction in Alzheimer's disease and strategies for treatment.

  2023cites this paper
• Proteasome inhibition protects blood–brain barrier P-glycoprotein and lowers Aβ brain levels in an Alzheimer’s disease model

  2023cites this paper
• Cu(ATSM) Increases P-Glycoprotein Expression and Function at the Blood-Brain Barrier in C57BL6/J Mice

  2023cites this paper
• Interaction of amisulpride with GLUT1 at the blood-brain barrier. Relevance to Alzheimer’s disease

  2023cites this paper
• Cellular senescence and the blood–brain barrier: Implications for aging and age-related diseases

  2023cites this paper
• ABCB1 and ABCG2 Regulation at the Blood-Brain Barrier: Potential New Targets to Improve Brain Drug Delivery

  2023cites this paper
• Endothelial Glycocalyx in Aging and Age-related Diseases

  2023cites this paper
• Role of microbial dysbiosis in the pathogenesis of Alzheimer's disease.

  2023cites this paper
• Reconsidering the role of blood-brain barrier in Alzheimer’s disease: From delivery to target

  2023cites this paper
• The relationship among amyloid-β deposition, sphingomyelin level, and the expression and function of P-glycoprotein in Alzheimer’s disease pathological process

  2022influential citation
• Beyond the classical amyloid hypothesis in Alzheimer's disease: Molecular insights into current concepts of pathogenesis, therapeutic targets, and study models.

  2022cites this paper
• Endothelial LRP1-ICD Accelerates Cognition-Associated Alpha-Synuclein Pathology and Neurodegeneration through PARP1 Activation in a Mouse Model of Parkinson’s Disease

  2022cites this paper
• Assessment of Aging-Related Function Variations of P-gp Transporter in Old-Elderly Chinese CHF Patients Based on Modeling and Simulation

  2022cites this paper
• Multifunctional nanomedicine strategies to manage brain diseases

  2022cites this paper
• Air Pollution Exposure Increases ABCB1 and ASCT1 Transporter Levels in Mouse Cortex.

  2022cites this paper
• A Review of Proteins Associated With Neuroprotection and Regeneration in Alzheimer's Disease

  2022cites this paper
• The Gut Microbiome and Alzheimer's Disease: Complex and Bidirectional Interactions.

  2022cites this paper
• Choroid Plexus in Alzheimer’s Disease—The Current State of Knowledge

  2022cites this paper
• Transporter Regulation in Critical Protective Barriers: Focus on Brain and Placenta

  2022cites this paper
• Blood–Brain Barrier Dysfunction and Astrocyte Senescence as Reciprocal Drivers of Neuropathology in Aging

  2022cites this paper
• Copper bis(thiosemicarbazone) complexes modulate P‐glycoprotein expression and function in human brain microvascular endothelial cells

  2022cites this paper
• The Ubiquitin E3 Ligase Nedd4 Regulates the Expression and Amyloid-β Peptide Export Activity of P-Glycoprotein

  2022cites this paper
• Healthy aging and the blood–brain barrier

  2021cites this paper
• Treating viruses in the brain: Perspectives from NeuroAIDS.

  2021cites this paper
• Blood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice

  2021cites this paper
• A Fundamental Role for Oxidants and Intracellular Calcium Signals in Alzheimer’s Pathogenesis—And How a Comprehensive Antioxidant Strategy May Aid Prevention of This Disorder

  2021cites this paper
• Role of the gut microbiome in Alzheimer’s disease

  2021cites this paper
• Disease-Induced Modulation of Drug Transporters at the Blood–Brain Barrier Level

  2021cites this paper
• Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles

  2021cites this paper
• Contribution of Gut Microbiota to Immunological Changes in Alzheimer’s Disease

  2021cites this paper
• Blood–Brain Barrier and Neurodegenerative Diseases—Modeling with iPSC-Derived Brain Cells

  2021cites this paper
• First clinical assessment of [18F]MC225, a novel fluorine-18 labelled PET tracer for measuring functional P-glycoprotein at the blood–brain barrier

  2021cites this paper
• Blood–Brain Barrier Breakdown: An Emerging Biomarker of Cognitive Impairment in Normal Aging and Dementia

  2021cites this paper
• ATP-binding cassette transporters and neurodegenerative diseases.

  2021cites this paper
• From Neurodevelopmental to Neurodegenerative Disorders: The Vascular Continuum

  2021cites this paper
• Regulation of P-glycoprotein by miR-27a-3p at the brain endothelial barrier.

  2021cites this paper
• Immunosenescence and Alzheimer’s Disease

  2021cites this paper
• Computational model of brain endothelial cell signaling pathways predicts therapeutic targets for cerebral pathologies.

  2021cites this paper
• Co-Expression Network Analysis of Micro-RNAs and Proteins in the Alzheimer’s Brain: A Systematic Review of Studies in the Last 10 Years

  2021cites this paper
• A Comprehensive Review of Alzheimer’s Association with Related Proteins: Pathological Role and Therapeutic Significance

  2020cites this paper
• Clinical and Genetic Risk Prediction of Cognitive Impairment After Blood or Marrow Transplantation for Hematologic Malignancy.

  2020cites this paper
• New Evidence for P-gp-Mediated Export of Amyloid-β Peptides in Molecular, Blood-Brain Barrier and Neuronal Models

  2020cites this paper
• PET Imaging of ABC Transporters at the Blood-Brain Barrier

  2020cites this paper
• From Brain to Heart: Possible Role of Amyloid-β in Ischemic Heart Disease and Ischemia-Reperfusion Injury

  2020cites this paper
• Protective Role of St. John’s Wort and Its Components Hyperforin and Hypericin against Diabetes through Inhibition of Inflammatory Signaling: Evidence from In Vitro and In Vivo Studies

  2020cites this paper
• Transport of Alzheimer’s associated amyloid-β catalyzed by P-glycoprotein

  2020cites this paper
• Mamma Mia, P‐glycoprotein binds again

  2020cites this paper
• A Perspective on Roles Played by Immunosenescence in the Pathobiology of Alzheimer's Disease

  2020cites this paper
• Impaired Clearance From the Brain Increases the Brain Exposure to Metoclopramide in Elderly Subjects

  2020cites this paper
• Klotho overexpression improves amyloid‐β clearance and cognition in the APP/PS1 mouse model of Alzheimer's disease

  2020cites this paper
• Abundance of P‐Glycoprotein and Other Drug Transporters at the Human Blood‐Brain Barrier in Alzheimer’s Disease: A Quantitative Targeted Proteomic Study

  2020cites this paper
• Blood-brain barrier integrity in the pathogenesis of Alzheimer's disease.

  2020cites this paper
• Blood–brain barrier: mechanisms governing permeability and interaction with peripherally acting μ-opioid receptor antagonists

  2020cites this paper
• Pharmacological Interactions in the Elderly

  2020cites this paper
• Protecting P-glycoprotein at the blood–brain barrier from degradation in an Alzheimer’s disease mouse model

  2020cites this paper
• Expression of P-gp in Glioblastoma: What we can Learn from Brain Development.

  2020cites this paper
• Contributions of Drug Transporters to Blood-Brain Barriers.

  2019cites this paper
• Age-Associated Changes in the Immune System and Blood–Brain Barrier Functions

  2019cites this paper
• Neuropharmacokinetics: a bridging tool between CNS drug development and therapeutic outcome.

  2019cites this paper
• Nanolipidic Carriers as Potential Drug Delivery Vehicles in Alzheimer’s Disease

  2019cites this paper
• P‐glycoprotein: a role in the export of amyloid‐β in Alzheimer's disease?

  2019cites this paper
• Age-Related Functional and Expressional Changes in Efflux Pathways at the Blood-Brain Barrier

  2019cites this paper
• Alterations in Expression and Function of ABC Family Transporters at Blood-Brain Barrier under Liver Failure and Their Clinical Significances

  2018cites this paper
• Efflux proteins at the blood–brain barrier: review and bioinformatics analysis

  2018cites this paper
• Associations between CSF cortisol and CSF norepinephrine in cognitively normal controls and patients with amnestic MCI and AD dementia

  2018cites this paper
• Intact blood‐brain barrier transport of small molecular drugs in animal models of amyloid beta and alpha‐synuclein pathology

  2018cites this paper
• Drug Response And Metabolism In Crohn's Disease

  2018cites this paper
• The Delivery Challenge in Neurodegenerative Disorders: The Nanoparticles Role in Alzheimer’s Disease Therapeutics and Diagnostics

  2018cites this paper
• Elimination of substances from the brain parenchyma: efflux via perivascular pathways and via the blood–brain barrier

  2018cites this paper
• Challenges and innovations of drug delivery in older age

  2018cites this paper
• SPECT and PET imaging in Alzheimer’s disease

  2018cites this paper
• Preventing P-gp Ubiquitination Lowers Aβ Brain Levels in an Alzheimer’s Disease Mouse Model

  2018cites this paper
• Clearance of Amyloid Beta and Tau in Alzheimer’s Disease: from Mechanisms to Therapy

  2018cites this paper
• Interaction between blood‐brain barrier and glymphatic system in solute clearance

  2018cites this paper
• Effect of P‐glycoprotein inhibition at the blood–brain barrier on brain distribution of (R)‐[11C]verapamil in elderly vs. young subjects

  2017cites this paper
• Cellular Models and In Vitro Assays for the Screening of modulators of P-gp, MRP1 and BCRP

  2017cites this paper
• Abcb1a but not Abcg2 played a predominant role in limiting the brain distribution of Huperzine A in mice.

  2017cites this paper